SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/327881"
 

Search: onr:"swepub:oai:gup.ub.gu.se/327881" > Differential respon...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Differential response to donepezil in MRI subtypes of mild cognitive impairment

Diaz-Galvan, P. (author)
Lorenzon, G. (author)
Karolinska Institutet
Mohanty, R. (author)
Karolinska Institutet
show more...
Martensson, G. (author)
Cavedo, E. (author)
Lista, S. (author)
Vergallo, A. (author)
Kantarci, K. (author)
Hampel, H. (author)
Dubois, B. (author)
Grothe, Michel J., 1981 (author)
Gothenburg University,Göteborgs universitet,Wallenberg Centre for Molecular and Translational Medicine
Ferreira, D. (author)
Karolinska Institutet
Westman, E. (author)
Karolinska Institutet
show less...
 (creator_code:org_t)
2023
2023
English.
In: Alzheimer's Research & Therapy. - 1758-9193. ; 15:1
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BackgroundDonepezil is an approved therapy for the treatment of Alzheimer's disease (AD). Results across clinical trials have been inconsistent, which may be explained by design-methodological issues, the pathophysiological heterogeneity of AD, and diversity of included study participants. We investigated whether response to donepezil differs in mild cognitive impaired (MCI) individuals demonstrating different magnetic resonance imaging (MRI) subtypes.MethodsFrom the Hippocampus Study double-blind, randomized clinical trial, we included 173 MCI individuals (donepezil = 83; placebo = 90) with structural MRI data, at baseline and at clinical follow-up assessments (6-12-month). Efficacy outcomes were the annualized percentage change (APC) in hippocampal, ventricular, and total grey matter volumes, as well as in the AD cortical thickness signature. Participants were classified into MRI subtypes as typical AD, limbic-predominant, hippocampal-sparing, or minimal atrophy at baseline. We primarily applied a subtyping approach based on continuous scale of two subtyping dimensions. We also used the conventional categorical subtyping approach for comparison.ResultsDonepezil-treated MCI individuals showed slower atrophy rates compared to the placebo group, but only if they belonged to the minimal atrophy or hippocampal-sparing subtypes. Importantly, only the continuous subtyping approach, but not the conventional categorical approach, captured this differential response.ConclusionsOur data suggest that individuals with MCI, with hippocampal-sparing or minimal atrophy subtype, may have improved benefit from donepezil, as compared with MCI individuals with typical or limbic-predominant patterns of atrophy. The newly proposed continuous subtyping approach may have advantages compared to the conventional categorical approach. Future research is warranted to demonstrate the potential of subtype stratification for disease prognosis and response to treatment.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Keyword

Randomized controlled trial
Donepezil
Mild cognitive impairment
Heterogeneity
Subtypes
Alzheimer's disease
Precision medicine
severe alzheimers-disease
hippocampal atrophy
cholinergic neurons
amnestic syndrome
defined subtypes
brain atrophy
double-blind
decline
dementia
system
Neurosciences & Neurology

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view